{"transactions":[{"id":3615970,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-03-05T21:17:14.000Z","date":"2019-03-01","kind":"other","acquired":false,"shares":280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2019-03-01","underlying":"Common Stock","underlying_shares":280},"source":{"system":"sec-edgar","filing":"0001127602-19-009924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219009924/form4.xml","form_type":"4"}},{"id":3615969,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-03-05T21:17:14.000Z","date":"2019-03-01","kind":"exercise","acquired":false,"shares":568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":280,"derivative":{"exercise_price":0,"expiration_date":"2019-03-01","underlying":"Common Stock","underlying_shares":568},"source":{"system":"sec-edgar","filing":"0001127602-19-009924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219009924/form4.xml","form_type":"4"}},{"id":3615968,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-03-05T21:17:14.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":253,"price":334.1,"value":84527.3,"ownership":{"direct":true},"balance_after":7234.631,"source":{"system":"sec-edgar","filing":"0001127602-19-009924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219009924/form4.xml","form_type":"4"}},{"id":3615967,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-03-05T21:17:14.000Z","date":"2019-03-01","kind":"exercise","acquired":true,"shares":568,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7487.631,"source":{"system":"sec-edgar","filing":"0001127602-19-009924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219009924/form4.xml","form_type":"4"}},{"id":3615966,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-03-05T21:17:14.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":405,"price":334.1,"value":135310.5,"ownership":{"direct":true},"balance_after":6919.631,"source":{"system":"sec-edgar","filing":"0001127602-19-009924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219009924/form4.xml","form_type":"4"}},{"id":3647592,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-02-20T23:07:30.000Z","date":"2019-02-15","kind":"other","acquired":false,"shares":888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":2338,"derivative":{"exercise_price":0,"expiration_date":"2020-02-15","underlying":"Common Stock","underlying_shares":888},"source":{"system":"sec-edgar","filing":"0001127602-19-007260","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219007260/form4.xml","form_type":"4"}},{"id":3647591,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-02-20T23:07:30.000Z","date":"2019-02-15","kind":"exercise","acquired":false,"shares":1448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":3226,"derivative":{"exercise_price":0,"expiration_date":"2020-02-15","underlying":"Common Stock","underlying_shares":1448},"source":{"system":"sec-edgar","filing":"0001127602-19-007260","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219007260/form4.xml","form_type":"4"}},{"id":3647590,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-02-20T23:07:30.000Z","date":"2019-02-15","kind":"tax_withholding","acquired":false,"shares":643,"price":332.87,"value":214035.41,"ownership":{"direct":true},"balance_after":7324.631,"source":{"system":"sec-edgar","filing":"0001127602-19-007260","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219007260/form4.xml","form_type":"4"}},{"id":3647589,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-02-20T23:07:30.000Z","date":"2019-02-15","kind":"exercise","acquired":true,"shares":1448,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7967.631,"source":{"system":"sec-edgar","filing":"0001127602-19-007260","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219007260/form4.xml","form_type":"4"}},{"id":3658379,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":10960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date])."}],"balance_after":10960,"derivative":{"exercise_price":0,"expiration_date":"2022-02-12","underlying":"Common Stock","underlying_shares":10960},"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":3658378,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"other","acquired":false,"shares":1357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date])."}],"balance_after":6314,"derivative":{"exercise_price":0,"expiration_date":"2021-02-12","underlying":"Common Stock","underlying_shares":1357},"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":3658377,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":1799,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date])."}],"balance_after":7671,"derivative":{"exercise_price":0,"expiration_date":"2021-02-12","underlying":"Common Stock","underlying_shares":1799},"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":3658376,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":1263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest in 2 annual installments.  One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date."}],"balance_after":2527,"derivative":{"exercise_price":0,"expiration_date":"2020-02-12","underlying":"Common Stock","underlying_shares":1263},"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":3658375,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"tax_withholding","acquired":false,"shares":539,"price":319.43,"value":172172.77,"ownership":{"direct":true},"balance_after":6519.631,"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":3658374,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":1799,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7058.631,"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":3658373,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"tax_withholding","acquired":false,"shares":380,"price":319.43,"value":121383.4,"ownership":{"direct":true},"balance_after":5259.631,"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":3658372,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2019-02-14T23:17:41.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":1263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018."}],"balance_after":5639.631,"source":{"system":"sec-edgar","filing":"0001127602-19-006088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760219006088/form4.xml","form_type":"4"}},{"id":4017546,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2018-03-05T21:41:16.000Z","date":"2018-03-01","kind":"other","acquired":false,"shares":312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":848,"derivative":{"exercise_price":0,"expiration_date":"2019-03-01","underlying":"Common Stock","underlying_shares":312},"source":{"system":"sec-edgar","filing":"0001127602-18-010088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218010088/form4.xml","form_type":"4"}},{"id":4017545,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2018-03-05T21:41:16.000Z","date":"2018-03-01","kind":"exercise","acquired":false,"shares":532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":1160,"derivative":{"exercise_price":0,"expiration_date":"2019-03-01","underlying":"Common Stock","underlying_shares":532},"source":{"system":"sec-edgar","filing":"0001127602-18-010088","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218010088/form4.xml","form_type":"4"}},{"id":4017544,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2018-03-05T21:41:16.000Z","date":"2018-03-01","kind":"tax_withholding","acquired":false,"shares":237,"price":282.35,"value":66916.95,"ownership":{"direct":true},"balance_after":4301.819,"source":{"system":"sec-edgar","filing":"0001127602-18-010088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218010088/form4.xml","form_type":"4"}},{"id":4017543,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2018-03-05T21:41:16.000Z","date":"2018-03-01","kind":"exercise","acquired":true,"shares":532,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4538.819,"source":{"system":"sec-edgar","filing":"0001127602-18-010088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218010088/form4.xml","form_type":"4"}},{"id":4017542,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2018-03-05T21:41:16.000Z","date":"2018-03-01","kind":"tax_withholding","acquired":false,"shares":405,"price":282.35,"value":114351.75,"ownership":{"direct":true},"balance_after":4006.819,"source":{"system":"sec-edgar","filing":"0001127602-18-010088","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218010088/form4.xml","form_type":"4"}},{"id":4049463,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2018-02-20T21:23:16.000Z","date":"2018-02-15","kind":"other","acquired":false,"shares":864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":4674,"derivative":{"exercise_price":0,"expiration_date":"2020-02-15","underlying":"Common Stock","underlying_shares":864},"source":{"system":"sec-edgar","filing":"0001127602-18-007206","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218007206/form4.xml","form_type":"4"}},{"id":4049462,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2018-02-20T21:23:16.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":1472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":5538,"derivative":{"exercise_price":0,"expiration_date":"2020-02-15","underlying":"Common Stock","underlying_shares":1472},"source":{"system":"sec-edgar","filing":"0001127602-18-007206","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218007206/form4.xml","form_type":"4"}},{"id":4049461,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2018-02-20T21:23:16.000Z","date":"2018-02-15","kind":"tax_withholding","acquired":false,"shares":442,"price":299.38,"value":132325.96,"ownership":{"direct":true},"balance_after":4411.819,"source":{"system":"sec-edgar","filing":"0001127602-18-007206","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218007206/form4.xml","form_type":"4"}},{"id":4049460,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2018-02-20T21:23:16.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":1472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 56.628 shares, 14.094 shares, 12.029 shares and 7.625 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2017, 6/30/2017, 9/29/2017 and 12/29/2017, respectively."}],"balance_after":4853.819,"source":{"system":"sec-edgar","filing":"0001127602-18-007206","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218007206/form4.xml","form_type":"4"}},{"id":4060777,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2018-02-14T23:41:25.000Z","date":"2018-02-12","kind":"grant","acquired":true,"shares":9470,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date])."}],"balance_after":9470,"derivative":{"exercise_price":0,"expiration_date":"2021-02-12","underlying":"Common Stock","underlying_shares":9470},"source":{"system":"sec-edgar","filing":"0001127602-18-006186","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218006186/form4.xml","form_type":"4"}},{"id":4060776,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2018-02-14T23:41:25.000Z","date":"2018-02-12","kind":"grant","acquired":true,"shares":3790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units will vest in 2 annual installments.  One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date."}],"balance_after":3790,"derivative":{"exercise_price":0,"expiration_date":"2020-02-12","underlying":"Common Stock","underlying_shares":3790},"source":{"system":"sec-edgar","filing":"0001127602-18-006186","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760218006186/form4.xml","form_type":"4"}},{"id":4406689,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2017-03-03T23:07:27.000Z","date":"2017-03-01","kind":"other","acquired":false,"shares":363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":1692,"derivative":{"exercise_price":0,"expiration_date":"2019-03-01","underlying":"Common Stock","underlying_shares":363},"source":{"system":"sec-edgar","filing":"0001127602-17-010305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217010305/form4.xml","form_type":"4"}},{"id":4406688,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2017-03-03T23:07:27.000Z","date":"2017-03-01","kind":"exercise","acquired":false,"shares":481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This award was previously reported as covering 2,480 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout.  One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.  The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"This award was previously reported as covering 2,480 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This award was previously reported as covering 2,480 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ, Inc. on February 1, 2017"}],"balance_after":2055,"derivative":{"exercise_price":0,"expiration_date":"2019-03-01","underlying":"Common Stock","underlying_shares":481},"source":{"system":"sec-edgar","filing":"0001127602-17-010305","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217010305/form4.xml","form_type":"4"}},{"id":4406687,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2017-03-03T23:07:27.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":2730,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3291.443,"source":{"system":"sec-edgar","filing":"0001127602-17-010305","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217010305/form4.xml","form_type":"4"}},{"id":4406686,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2017-03-03T23:07:27.000Z","date":"2017-03-01","kind":"tax_withholding","acquired":false,"shares":157,"price":293.26,"value":46041.82,"ownership":{"direct":true},"balance_after":561.443,"source":{"system":"sec-edgar","filing":"0001127602-17-010305","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217010305/form4.xml","form_type":"4"}},{"id":4406685,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Common Stock","published_at":"2017-03-03T23:07:27.000Z","date":"2017-03-01","kind":"exercise","acquired":true,"shares":481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 27.114 shares acquired under the Biogen Inc. employee stock purchase plan on 9/30/2016 and 12/30/2016."}],"balance_after":718.443,"source":{"system":"sec-edgar","filing":"0001127602-17-010305","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217010305/form4.xml","form_type":"4"}},{"id":4440894,"issuer":{"id":1675,"kind":"organization","name":"BIOGEN INC.","symbol":"BIIB"},"owners":[{"id":159553,"kind":"person","name":"McKenzie Paul","position":1,"cik":"0001677903","reported_name":"McKenzie Paul","relationship":{"officer":true,"officer_title":"EVP Pharmaceutical Oper & Tech"}}],"security":"Restricted Stock Unit","published_at":"2017-02-18T01:19:56.000Z","date":"2017-02-15","kind":"grant","acquired":true,"shares":7010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date])."}],"balance_after":7010,"derivative":{"exercise_price":0,"expiration_date":"2020-02-15","underlying":"Common Stock","underlying_shares":7010},"source":{"system":"sec-edgar","filing":"0001127602-17-007109","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875045/000112760217007109/form4.xml","form_type":"4"}}]}